Benralizumab Emerging Drug Insight and Market Forecast - 2032

Benralizumab Emerging Drug Insight and Market Forecast − 2032

“Benralizumab Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about benralizumab for Chronic Spontaneous Urticaria in seven major markets. A detailed picture of the benralizumab for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the benralizumab for Chronic Spontaneous Urticaria. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the benralizumab market forecast analysis for Chronic Spontaneous Urticaria in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Chronic Spontaneous Urticaria.

Drug Summary

Fasenra (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death).

Fasenra is AstraZeneca’s first respiratory biologic, now approved as an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan, and other countries, with further regulatory reviews ongoing. In the US, Fasenra is approved for self-administration using the Fasenra Pen. In the EU, Fasenra is approved for self-administration in either the single-use, prefilled syringe, or the Fasenra Pen. Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Kirin Co., Ltd., Japan. MedImmune is the worldwide biologics research and development arm of AstraZeneca, and thus, both AstraZeneca and MedImmune are working together for the development of benralizumab.

The three new trials for Fasenra in skin diseases include two ‘phase II trials’ to assess the potential of the medicine in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU); and a phase III trial in bullous pemphigoid (BP).

Scope of the Report

The report provides insights into:

A comprehensive product overview including the benralizumab description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria.

Elaborated details on benralizumab regulatory milestones and other development activities have been provided in this report.

The report also highlights the benralizumab research and development activities in Chronic Spontaneous Urticaria across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around benralizumab.

The report contains forecasted sales of benralizumab for Chronic Spontaneous Urticaria till 2032.

Comprehensive coverage of the late-stage emerging therapies for Chronic Spontaneous Urticaria.

The report also features the SWOT analysis with analyst views for benralizumab in Chronic Spontaneous Urticaria.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Benralizumab Analytical Perspective by DelveInsight

In-depth Benralizumab Market Assessment

This report provides a detailed market assessment of benralizumab for Chronic Spontaneous Urticaria in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

Benralizumab Clinical Assessment

The report provides the clinical trials information of benralizumab for Chronic Spontaneous Urticaria covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence benralizumab dominance.

Other emerging products for Chronic Spontaneous Urticaria are expected to give tough market competition to benralizumab and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of benralizumab in Chronic Spontaneous Urticaria.

Our in-depth analysis of the forecasted sales data of benralizumab from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the benralizumab in Chronic Spontaneous Urticaria.

Key Questions

What is the product type, route of administration and mechanism of action of benralizumab?

What is the clinical trial status of the study related to benralizumab in Chronic Spontaneous Urticaria and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the benralizumab development?

What are the key designations that have been granted to benralizumab for Chronic Spontaneous Urticaria?

What is the forecasted market scenario of benralizumab for Chronic Spontaneous Urticaria?

What are the forecasted sales of benralizumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to benralizumab for Chronic Spontaneous Urticaria?

Which are the late-stage emerging therapies under development for the treatment of Chronic Spontaneous Urticaria?